While it may ultimately be impossible to verify why exactly a clinical-stage biotech would delay a potential new drug approval, Relay Therapeutics said yesterday that it will push back seeking approval for its potential FGFR2 selective inhibitor RLY-4008 (lirafugratinib) in bile duct cancer to wait for a larger indication because…
Click here to view original post
